<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[aaron f. barkoff Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/aaron+f.+barkoff.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to aaron f. barkoff]]></description>
	<s:counts start="0" returned="4" found="4" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Bayer Patent on Yasmin Affirmed Invalid]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F154268-bayer-patent-on-yasmin-affirmed-invalid%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Aaron F. Barkoff submits:  Bayer Schering v. Barr Labs, No. 2008-1282 (Fed. Cir. 2009) A divided panel of the Federal Circuit affirmed a district court decision holding Bayer's (BYERF.PK) U.S. Patent No. 6,787,531 invalid due to obviousness.  The '531 patent, which claims pharmaceutical compositions of drospirenone and ethinyl...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 06 Aug 2009 05:27:26 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/aaron+f.+barkoff.html"><![CDATA[Aaron F. Barkoff]]></category>
	</item>
	<item>
		<title><![CDATA[Supreme Court Denies Aventis' Cert Petition in Lovenox Case]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F133850-supreme-court-denies-aventis-cert-petition-in-lovenox-case%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Aaron F. Barkoff submits:  Aventis Pharma v. Amphastar and Teva, S. Ct. Appeal No. 08-937 (2009)   The Supreme Court on Monday denied Aventis Pharma's SNY cert petition in a long-running dispute with generic biopharmaceutical manufacturer Amphastar.  In its petition, Aventis had asked the Court to review...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 28 Apr 2009 11:17:39 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/aaron+f.+barkoff.html"><![CDATA[Aaron F. Barkoff]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi-aventis.html"><![CDATA[Sanofi-Aventis]]></category>
	</item>
	<item>
		<title><![CDATA[Federal Circuit Affirms Extension of Stay Against Teva's Generic Evista]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F122485-federal-circuit-affirms-extension-of-stay-against-teva-s-generic-evista%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Aaron F. Barkoff submits:  Eli Lilly & Co. LLY v. Teva Pharms. TEVA USA, Inc., No. 2009&#8211;1071 (Fed. Cir. 2009) Under the Hatch-Waxman Act, final FDA approval of an ANDA is automatically stayed for thirty months when a patent owner files suit for patent infringement within 45 days of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Feb 2009 12:56:01 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/aaron+f.+barkoff.html"><![CDATA[Aaron F. Barkoff]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Federal Circuit Affirms Fee Award to Takeda]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F109997-federal-circuit-affirms-fee-award-to-takeda%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Aaron F. Barkoff submits:  Takeda v. Mylan and Alphapharm, Nos. 2007-1269, -1270 (Fed. Cir. 2008)   In an opinion released Monday, the Federal Circuit affirmed a district court decision granting $16.8 million for attorney fees, expenses and expert fees to Takeda (TKPHF.PK) for baseless paragraph IV certification letters...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 09 Dec 2008 10:50:26 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/aaron+f.+barkoff.html"><![CDATA[Aaron F. Barkoff]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
</channel>
</rss>
